新生儿卡介苗接种与2、6月龄结核菌素皮肤试验反应对1岁内死亡率的影响
在几内亚比绍三项卡介苗试验出生队列中,评估2月龄和6月龄结核菌素皮肤试验(TST)反应与随后至12月龄死亡风险的关系,并纳入文献进行荟萃分析。结果显示TST反应者死亡率降低,2月龄TST反应与全因死亡MRR为0.59(0.39-0.90)。改善接种技术和选用特定卡介苗菌株可能提高TST反应率,增强卡介苗非特异性有益效应。
要点
- 2月龄TST反应者2-12月龄死亡风险1.7%,非反应者3.3%,MRR=0.49(0.19-1.26)。
- 6月龄TST反应者6-12月龄死亡风险0.4%,非反应者0.6%,MRR=0.87(0.27-2.86)。
- 荟萃分析显示2月龄TST反应与全因死亡MRR=0.59(0.39-0.90)。
核心结论
- 在卡介苗接种婴儿中,TST反应与死亡率显著降低相关。
- 改善接种技术和使用特定卡介苗菌株可能提高TST反应率,增强卡介苗非特异性有益效应。
研究设计与样本
- 观察性研究,嵌套于三项几内亚比绍卡介苗试验出生队列(2002-04、2009-2013、2014-18)。
- 纳入28天内接种卡介苗的儿童,2月龄TST检测n=1389,6月龄TST检测n=2635。
- 采用二项回归分析TST反应决定因素,Cox模型计算死亡率比(MRR),并检索PubMed进行荟萃分析。
主要发现
- 接种后大卡痕与6月龄TST阳性相关,接种BCG-Denmark或BCG-Japan较BCG-Russia更易出现TST阳性。
- 2月龄TST反应者占22%(302/1389),2-12月龄死亡风险1.7%(5/302),非反应者3.3%(36/1087),MRR=0.49(0.19-1.26)。
- 6月龄TST反应者占44%(1149/2635),6-12月龄死亡风险0.4%(4/1149),非反应者0.6%(9/1486),MRR=0.87(0.27-2.86)。
- 文献检索获得3项研究,荟萃分析显示TST反应与死亡率降低一致相关,2月龄TST反应MRR=0.59(0.39-0.90),6月龄TST反应MRR=0.65(0.43-1.00)。
关键数值与推荐
- TST反应定义为>1 mm,非反应定义为≤1 mm。
- 2月龄TST反应与全因死亡MRR=0.59(0.39-0.90);6月龄TST反应MRR=0.65(0.43-1.00)。
临床怎么用
- 卡介苗接种后TST反应可作为非特异性保护效应的潜在标志,但需结合接种技术和菌株选择综合评估。
- 改善卡介苗接种技术、选用可提高TST反应率的菌株,可能增强卡介苗对婴儿存活的有益效应。
局限性
- 观察性研究设计,可能存在残余混杂。
- 2月龄和6月龄TST反应与死亡关联的置信区间较宽,精确性有限。
- 荟萃分析仅纳入3项研究,证据基础有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In randomized trials, Bacille Calmette-Guérin (BCG) vaccine has been associated with reduced all-cause mortality. BCG-induced Tuberculin Skin Test (TST) reactions have also been associated with reduced all-cause mortality. We aimed to assess the association between TST responses and subsequent mortality in three birth cohorts and conducted a meta-analysis of existing studies. METHODS: Observational study within three Guinea-Bissau BCG trial birth cohorts (conducted 2002-04, 2009-2013 and 2014-18) that encompassed children who were BCG-vaccinated within 28 days with TSTs performed at 2- (n = 1389) and 6-months (n = 2635) of age. We evaluated TST reaction determinants by binomial regression and assessed the association between TSTs > 1 mm (reactors) vs. ≤ 1 mm (non-reactors) and subsequent mortality risk up to age 12 months in Cox-models providing Mortality Rate Ratios (MRRs). We searched PubMed for studies to calculate meta-estimates of the association between TST reactivity by age 2- and 6-months and all-cause mortality. RESULTS: Large post-vaccination wheal size was associated with 6-month TST positivity and so was receiving BCG-Denmark or BCG-Japan, compared with BCG-Russia. By age 2 months, 22% (302/1389) of infants were TST reactors with a 2-12-month mortality risk of 1.7% (5/302) vs. 3.3% (36/1087) for non-reactors, the corresponding reactor/non-reactor MRR = 0.49 (0.19-1.26). By age 6 months, 44% (1149/2635) of infants were reactors and the 6-12-month mortality risk was 0.4% (4/1149) vs. 0.6% (9/1486) for non-reactors, the MRR = 0.87 (0.27-2.86). The literature search provided 3 studies. The meta-analysis revealed a uniform pattern of reduced mortality associated with TST reactivity, a TST response by 2 months being associated with an MRR of 0.59 (0.39-0.90); for 6-month TST responses the MRR was 0.65 (0.43-1.00). CONCLUSION: Among BCG-vaccinated infants, TST reactions were associated with markedly reduced mortality. Improved vaccination technique and using certain BCG strains could lead to a higher TST reaction prevalence, which would enhance BCG's beneficial non-specific effects.
引用
- Schaltz-Buchholzer F, Roth A, de Bree LCJ, et al. Neonatal Bacille Calmette-Guérin vaccination and tuberculin skin test reactions at 2- and 6-months: Effects on mortality up to 1 year of age. Vaccine. 2021. PMID: 34226104. doi:10.1016/j.vaccine.2021.06.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。